Related Experiment Videos
Sodium valproate does not alter immune competence in mice
J P Brouland1, A Perriat, J P Revillard
1Laboratoire d'Immunotoxicologie, INSERM U80-CNRS URA 1177-UCBL, Faculté de Médecine Alexis Carrel, Lyon, France.
Immunopharmacology and Immunotoxicology
|January 1, 1989
Summary
Sodium valproate, an epilepsy medication, showed minimal impact on the immune system in mice. Key immune responses like delayed-type hypersensitivity and plaque-forming cells were only slightly affected, suggesting it does not significantly alter immune competence.
Area of Science:
- Immunology
- Pharmacology
Background:
- Sodium valproate (SV) is widely used for epilepsy and bipolar disorder.
- Its potential effects on the immune system require thorough investigation.
Purpose of the Study:
- To evaluate the impact of sodium valproate on various immune parameters in a mouse model.
- To determine if SV significantly alters immune competence.
Main Methods:
- Swiss mice were administered sodium valproate (250 mg/kg/day) orally for 21 days.
- Assessed spleen and thymus weight, delayed-type hypersensitivity (DTH), contact hypersensitivity, antibody titers, plaque-forming cells (PFC), resistance to toxoplasmosis, and IgA levels.
Main Results:
- Sodium valproate did not cause significant alterations in most immune parameters.
- A slight modification was observed in DTH responses to sheep red blood cells (SRBC) and PFC counts.
Conclusions:
- Sodium valproate is unlikely to markedly affect overall immune competence.
- Further research may explore subtle immunomodulatory effects if any.